A Complete Guide to Patent Expiry, CDSCO Approval, and What It Means for You
| KEY TAKEAWAYSIndia’s Section 3(d) patent law has cleared the path for domestic pharma companies to manufacture generic semaglutide as key compound patents expire.Any CDSCO-approved generic must pass bioequivalence testing, confirming the same clinical performance as the branded reference product.A valid prescription from a registered physician, endocrinologist, or diabetologist is required for legal access in India. |
If you have been searching for a clear, reliable answer on where things stand with generic semaglutide in India, you are in the right place.
This guide walks through the patent landscape, the manufacturers entering the space, the clinical evidence, and everything you need to know about safe, legitimate access.
1. What Is Semaglutide and Why Is India Paying Attention?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of medication originally developed to manage type 2 diabetes.
It works by mimicking a naturally occurring gut hormone that signals the pancreas to release insulin, slows gastric emptying, and reduces appetite signals in the brain.
India carries one of the world’s largest diabetes burdens. The ICMR-INDIAB National Study, published in The Lancet Diabetes and Endocrinology, found that an estimated 101 million adults in India were living with diabetes as of 2023.
Access to effective therapies in this category has genuine public health significance.
The medication is available in three formulations. A lower-dose injectable version, Ozempic, manages type 2 diabetes by improving blood sugar control. A higher-dose injectable version, Wegovy, is approved specifically for long-term weight management. An oral tablet version, Rybelsus, is also available for type 2 diabetes management. All three work through the same GLP-1 mechanism; the differences lie in dose, formulation, and the approved clinical indication.
The STEP 1 clinical trial, published in The New England Journal of Medicine, found that participants without diabetes who received semaglutide 2.4 mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo.
Results on that scale had not been seen in a once-weekly injectable before these trials.
Metabolic conditions including type 2 diabetes, non-alcoholic fatty liver disease, and obesity-related cardiovascular risk are rising sharply among working-age adults across India. A practical, accessible pharmaceutical option in this category represents a meaningful shift in how metabolic health can be managed at scale.
2. How India’s Patent Framework Opened the Door for Generics
India’s intellectual property framework for pharmaceutical patents is designed to balance innovation incentives with public health access.
The cornerstone is Section 3(d) of the Patents Act, 1970, which prevents pharmaceutical companies from receiving new patents on modified or reformulated versions of existing substances unless the new form demonstrates significantly enhanced therapeutic efficacy.
This provision gained global attention through the landmark Novartis AG v. Union of India judgment in 2013, where the Supreme Court upheld the rejection of a patent application for a reformulated cancer medication.
That ruling established clear precedent: incremental chemical modifications do not automatically qualify for patent protection in India.
Novo Nordisk holds a portfolio of patents related to semaglutide, covering the compound, specific formulations, delivery mechanisms, and manufacturing processes.
As these patents approach expiry or face scrutiny under Indian patent law, domestic manufacturers gain a legal pathway to produce generic versions of the same active molecule.
Under India’s patent regime, once a compound patent expires or is not granted, any licensed manufacturer can produce and market that active pharmaceutical ingredient, provided they satisfy regulatory requirements. This is the intended structure of Indian pharmaceutical policy, one that has historically positioned India as a global supplier of affordable generic medicines.
When the legal barrier is removed, the only remaining gate is regulatory approval.
Source: The Patents Act, 1970, Section 3(d), Intellectual Property India
3. Which Indian Pharma Companies Are Entering the Generic Semaglutide Space?
Several of India’s largest pharmaceutical manufacturers have announced development activity or regulatory filings related to semaglutide generics.
India’s established expertise in peptide synthesis, built over decades of supplying biosimilar insulins and other complex molecules to global markets, has positioned domestic companies well for this transition.
Sun Pharma, India’s largest pharmaceutical company and the fourth-largest specialty generic pharmaceutical company globally, has a broad diabetes and metabolic disorder portfolio.
Their specialty drug capabilities and regulatory relationships with CDSCO make them a natural candidate in this space.
Biocon, a pioneer in biologics and biosimilar manufacturing in India, brings specific expertise in peptide-based drug production. Semaglutide requires sophisticated synthesis capabilities that Biocon’s infrastructure is built around.
Dr. Reddy’s Laboratories and Cipla, both with established CDSCO and international regulatory track records, are among the companies monitoring or actively pursuing this segment. Natco Pharma, known for its approach to patent challenges on high-value molecules, is also a candidate given its consistent track record.
| Company | Core Strength | Diabetes Portfolio | Regulatory Footprint |
| Sun Pharma | Specialty generics, formulation | Extensive oral and injectable range | CDSCO, USFDA, EMA |
| Biocon | Biologics, peptide synthesis | Biosimilar insulins | CDSCO, WHO, USFDA |
| Dr. Reddy’s | API + finished formulations | Broad generic coverage | CDSCO, USFDA, EMA |
| Cipla | Broad generic manufacturing | Diabetes injectables | CDSCO, USFDA, SAHPRA |
| Natco Pharma | Patent challenge specialist | Growing metabolic pipeline | CDSCO, USFDA |
Important: Approval status changes rapidly. Always verify the current CDSCO-approved list of semaglutide products at cdsco.gov.in before making any purchase decisions.
4. Is Generic Semaglutide as Effective as Ozempic? Here Is What the Evidence Says
A generic drug contains the same active pharmaceutical ingredient (API) at the same dose, delivered through the same route. Clinical outcomes are tied to the molecule, not the brand. What may differ are inactive excipients or device design.
CDSCO requires generic manufacturers to demonstrate bioequivalence: proof that the generic is absorbed at essentially the same rate and extent as the reference branded product.
International regulatory standards define bioequivalence as pharmacokinetic parameters falling within 80 to 125% of the reference product values.
The foundational clinical evidence comes from the SUSTAIN trial program (for type 2 diabetes management) and the STEP trial program (for weight management). These results belong to the semaglutide molecule itself, not to any specific brand.
| Trial | Population | Primary Outcome | Journal |
| STEP 1 (Wilding et al., 2021) | Obesity, no diabetes | Mean body weight loss: 14.9% vs 2.4% placebo | NEJM |
| STEP 2 (Davies et al., 2021) | Obesity with type 2 diabetes | Mean body weight loss: 9.6% vs 3.4% placebo | Lancet |
| SUSTAIN 6 (Marso et al., 2016) | Type 2 diabetes | 26% reduction in major CV events vs placebo | NEJM |
| SELECT (Lincoff et al., 2023) | Overweight/obesity, established CVD | 20% reduction in major adverse cardiovascular events | NEJM |
The SELECT trial, published in The New England Journal of Medicine in 2023, was particularly significant.
It demonstrated a 20% reduction in major adverse cardiovascular events in participants with overweight or obesity and established cardiovascular disease, with no requirement for a diabetes diagnosis.
This expanded the clinical relevance of the semaglutide molecule well beyond blood glucose management.
A generic that successfully demonstrates bioequivalence to the reference product can be expected to produce clinically comparable results across these outcome categories.
Read the source trials: STEP 1 (NEJM, 2021) | SUSTAIN 6 (NEJM, 2016) | SELECT (NEJM, 2023)
5. Side Effects You Should Know Before You Start
Semaglutide has a well-characterized safety profile built across thousands of participants in multiple large-scale trials.
That does not mean it is free of side effects. Knowing what to expect helps you and your physician plan the right dosing approach.
The most common side effects are gastrointestinal. In the STEP 1 trial, nausea was reported by approximately 44% of participants in the semaglutide group, compared to 16% in the placebo group.
Vomiting, diarrhea, and constipation are also frequently reported. Most gastrointestinal symptoms are dose-dependent and tend to decrease after the initial weeks of treatment, particularly when doses are titrated gradually.
Less common but clinically significant risks include pancreatitis, thyroid C-cell concerns, increased hypoglycemia risk when combined with insulin or sulfonylureas, and gallbladder disease related to rapid weight change.
Any severe or persistent abdominal pain should be reported to your doctor immediately.
| Contraindication | Clinical Reason |
| Personal or family history of medullary thyroid carcinoma | Potential thyroid C-cell risk identified in animal studies |
| Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) | Associated thyroid carcinoma risk |
| History of pancreatitis | May worsen pancreatic inflammation |
| Pregnancy or breastfeeding | Insufficient safety data currently available |
| Severe renal impairment | Limited data; requires physician-led assessment |
Disclose your complete medical history to your physician before starting any semaglutide product, branded or generic.
6. How Do You Actually Get a Prescription for Generic Semaglutide in India?
Semaglutide in India is classified as a Schedule H drug under the Drugs and Cosmetics Act, 1940.
This classification means it is not available over the counter and requires a valid prescription from a registered medical practitioner.
Who can prescribe it:
- Endocrinologists for both type 2 diabetes and obesity with metabolic complications
- Diabetologists for blood glucose management indications
- General physicians and internists within their scope of practice
- Obesity medicine specialists, an increasingly available specialty in India’s major cities
Begin with a consultation with an endocrinologist or your primary care physician.
Your doctor will assess your HbA1c levels, BMI, cardiovascular risk profile, kidney function, and current medication list. Semaglutide is not clinically appropriate for everyone.
Semaglutide for weight management is typically indicated for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above when accompanied by a weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia.
Take your prescription to a registered pharmacy or hospital dispensary carrying CDSCO-approved semaglutide products.
Do not source semaglutide from unverified online platforms, grey market vendors, or any seller who does not require a prescription.
CDSCO-approved generics carry the manufacturer’s name, batch number, manufacturing license number, and the Schedule H cautionary label on the packaging.
When collecting your medication, verify that the product name, manufacturer, and dose on the packaging match exactly what your physician prescribed. Ask the pharmacist to confirm the CDSCO registration number if in doubt.
7. What Does CDSCO Approval Actually Mean for Your Safety?
The Central Drugs Standard Control Organisation (CDSCO) is India’s national regulatory authority for pharmaceuticals, operating under the Ministry of Health and Family Welfare.
It functions in a role broadly parallel to the USFDA in the United States or the EMA in Europe.
For a generic semaglutide product to receive CDSCO approval, the manufacturer must submit:
- Pharmaceutical equivalence data confirming the same API, dose, and dosage form as the reference product
- Bioequivalence study results from appropriate clinical or pharmacokinetic testing
- Good Manufacturing Practice (GMP) certification of the manufacturing facility
- Stability data confirming shelf life under Indian climatic storage conditions
- Labeling compliant with CDSCO requirements, including the Schedule H classification
Once approved, CDSCO-licensed generics are subject to ongoing post-market surveillance, including batch testing and adverse event reporting requirements.
CDSCO maintains a public database of approved drugs.
You can search by drug name or manufacturer to confirm whether a specific generic semaglutide product has received regulatory clearance.
That verification step takes under two minutes and is your most reliable safeguard against counterfeit or unapproved products.
| THE BOTTOM LINEGeneric semaglutide in India represents a meaningful shift in access to one of the most clinically significant metabolic medicines of the past decade.India’s patent framework, manufacturing infrastructure, and CDSCO oversight together create a clear pathway for safe, regulated alternatives to the branded product. The clinical evidence behind the semaglutide molecule is robust, with large-scale trials documenting consistent outcomes across diverse patient populations.Your next step: consult a qualified physician to determine whether semaglutide is appropriate for your situation, and rely only on CDSCO-approved products dispensed through a licensed pharmacy. You can also explore the MetaGo weight loss program for clinician-supervised semaglutide treatment in India. |
Frequently Asked Questions
Is generic semaglutide available in India right now?
Generic semaglutide products are entering the Indian market as compound patents expire and domestic manufacturers receive CDSCO approval.
Availability may vary by city and pharmacy. Confirm the current approved product list at cdsco.gov.in and ask your physician for up-to-date dispensing options in your area.
Is generic semaglutide as safe as Ozempic?
Any generic semaglutide approved by CDSCO has been required to demonstrate bioequivalence to the reference branded product and must be manufactured in GMP-compliant facilities.
The active molecule is identical, and the safety profile documented across the STEP and SUSTAIN trial programs applies to the semaglutide API regardless of brand. Always purchase from a licensed pharmacy with a valid prescription.
Can I buy semaglutide without a prescription in India?
No. Semaglutide is a Schedule H drug under the Drugs and Cosmetics Act, 1940, and legally requires a valid prescription from a registered medical practitioner.
Any vendor offering semaglutide without requesting a prescription is operating outside Indian law. This is not a medication to self-administer without professional medical supervision.
How does India’s patent law specifically affect semaglutide availability?
Section 3(d) of the Patents Act prevents pharmaceutical patent evergreening, meaning incremental modifications to an existing molecule cannot be automatically re-patented in India.
As Novo Nordisk’s core compound patents expire, Indian manufacturers can legally produce generic semaglutide without infringing on intellectual property, provided they obtain CDSCO approval and meet all manufacturing standards.
Which doctors in India prescribe semaglutide for weight loss?
Endocrinologists and obesity medicine specialists are the most common prescribers for weight management in India. Your physician will assess your BMI, metabolic risk factors, and overall health profile before recommending semaglutide.
It is typically indicated for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with a weight-related health condition such as type 2 diabetes, hypertension, or dyslipidemia.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or modifying any medication.
